The U.S. Food and Drug Administration (FDA) Approves Nivolumab for Hodgkin Lymphoma March 20, 2026- On March 20, 2026, the U.S. Food and Drug Administration (FDA) announced it has approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and…
The Lymphoma Research Foundation’s
Lymphoma Scientific Research Mentoring
Program (LSRMP) is a first-of-its-kind education and mentoring program for junior scientists
who wish to focus on lymphoma and CLL
research, whether in the lab or in the clinic.
Updates from the 2025 American Society of Hematology Annual Meeting The Lymphoma Research Foundation returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 276 Foundation-affiliated scientists, including past and present members of the Foundation’s world-leading Scientific…
Where Are They Now? Sanket Shah, PhD Sanket Shah, PhD, is currently a postdoctoral fellow at Weill Cornell Medicine. When did you become interested in the study of medicine? In lymphoma specifically? My interest in science started early. My father…
Patient Perspectives: Access to CAR T-Cell Therapy One of the most revolutionary breakthroughs in cancer care comes from within a patient’s own cells: chimeric antigen receptor (CAR) T-cell therapy, which harnesses the powers of the body’s immune system to hone…
Where Science Meets Compassion: How Allison Rosenthal, DO, Is Rewriting the Story of Lymphoma Care – One Patient at a Time When Allison Rosenthal, DO, walks into a patient’s room, she brings with her more than medical expertise. She brings…
Investing in a Cure: Robb Early’s Planned Gift of Hope When Robb Early felt two swollen areas in his groin during a wedding anniversary trip in September 2023, he never imagined the discovery would lead to a cancer diagnosis —…
ASH 2025: Association Between Adolescent and Young Adult (AYA) Age, Acuity of Illness at Diagnosis, and Clinical Trial Enrollment Among Patients with Hematologic Malignancies at a Pediatric Center Clinical trials represent an important opportunity to access cutting edge therapies in…
ASH 2025: Real-World Treatment Patterns, Patient Characteristics, and Outcomes of CBTKI-Based Therapies Amongst a Contemporary Cohort of Patients with R/R MCL in the United States Covalent Bruton tyrosine kinase inhibitors (cBTKis) have been a cornerstone of treatment for relapsed/refractory mantle…
ASH 2025: A Newly Identified Role for IL-5 in Regulating CAR T-associated Toxicity and Efficacy Chimeric antigen receptor (CAR) T-cell therapies have emerged as an important component of the treatment arsenal for B-cell malignancies. Their use, however, has been complicated…
